Clinical Trial Update: Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis [Phase 1, Phase 2]

View source ↗

Summary

This Phase I/II multi-dose rheumatoid arthritis trial compared LEA29Y with CTLA-4Ig and placebo and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CTLA-4Ig (CTLA-4-Ig fusion protein)
• LEA29Y

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: COMPLETED